{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:04:38Z","timestamp":1794002678371,"version":"4.8.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cellular immune responses have the potential to elicit dramatic and sustained clinical remissions in lymphoma patients. Recent clinical trial data demonstrate that modification of T cells with chimeric antigen receptors (CARs) is a promising strategy. T cells containing CARs with costimulatory domains exhibit improved activity against tumors. We conducted a pilot clinical trial testing a \u201cthird-generation\u201d CD20-specific CAR with CD28 and 4-1BB costimulatory domains in patients with relapsed indolent B-cell and mantle cell lymphomas. Four patients were enrolled, and 3 received T-cell infusions after cyclophosphamide lymphodepletion. Treatment was well tolerated, although one patient developed transient infusional symptoms. Two patients without evaluable disease remained progression-free for 12 and 24 months. The third patient had an objective partial remission and relapsed at 12 months after infusions. Modified T cells were detected by quantitative PCR at tumor sites and up to 1 year in peripheral blood, albeit at low levels. No evidence of host immune responses against infused cells was detected. In conclusion, adoptive immunotherapy with CD20-specific T cells was well tolerated and was associated with antitumor activity. We will pursue alternative gene transfer technologies and culture conditions in future studies to improve CAR expression and cell production efficiency. This study is registered at www.clinicaltrials.gov as NCT00621452.<\/jats:p>","DOI":"10.1182\/blood-2011-10-387969","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T20:18:06Z","timestamp":1328386686000},"page":"3940-3950","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":462,"title":["CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results"],"prefix":"10.1182","volume":"119","author":[{"given":"Brian G.","family":"Till","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Seattle Children's Research Institute, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Qian","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine G.","family":"Lindgren","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukang","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Raubitschek","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Research Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Research Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Riddell","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111811062866300_B1","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"issue":"18","key":"2019111811062866300_B2","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111811062866300_B3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019111811062866300_B4","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111811062866300_B5","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111811062866300_B6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111811062866300_B7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy.","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111811062866300_B8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2019111811062866300_B9","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.4049\/jimmunol.159.11.5509","article-title":"Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.","volume":"159","author":"Altenschmidt","year":"1997","journal-title":"J Immunol"},{"issue":"3","key":"2019111811062866300_B10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes costimulated by CD80 and interleukin-15.","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"issue":"2","key":"2019111811062866300_B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/bbmt.1998.v4.pm9763110","article-title":"CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.","volume":"4","author":"Jensen","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111811062866300_B12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2019111811062866300_B13","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111811062866300_B14","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111811062866300_B15","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2019111811062866300_B16","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111811062866300_B17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"issue":"22","key":"2019111811062866300_B18","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19- specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"2019111811062866300_B19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"4","key":"2019111811062866300_B20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2019111811062866300_B21","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111811062866300_B22","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2019111811062866300_B23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.","volume":"18","author":"Wang","year":"2007","journal-title":"Hum Gene Ther"},{"issue":"2","key":"2019111811062866300_B24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"issue":"5","key":"2019111811062866300_B25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111811062866300_B26","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/blood-2003-04-1255","article-title":"Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function.","volume":"102","author":"Nguyen","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111811062866300_B27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti\u2013CD3 and anti\u2013CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.","volume":"128","author":"Riddell","year":"1990","journal-title":"J Immunol Methods"},{"issue":"1","key":"2019111811062866300_B28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/mthe.1999.0012","article-title":"Human T lymphocyte genetic modification with naked DNA.","volume":"1","author":"Jensen","year":"2000","journal-title":"Mol Ther"},{"issue":"10","key":"2019111811062866300_B29","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/30.10.e47","article-title":"Telomere measurement by quantitative PCR.","volume":"30","author":"Cawthon","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2019111811062866300_B30","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111811062866300_B31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4049\/jimmunol.0901101","article-title":"MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.","volume":"184","author":"Li","year":"2010","journal-title":"J Immunol"},{"issue":"7","key":"2019111811062866300_B32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"6","key":"2019111811062866300_B33","first-page":"1671","article-title":"Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.","volume":"48","author":"Berd","year":"1988","journal-title":"Cancer Res"},{"issue":"4","key":"2019111811062866300_B34","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"issue":"4","key":"2019111811062866300_B35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"issue":"27","key":"2019111811062866300_B36","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1182\/blood-2009-08-232967","article-title":"Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.","volume":"114","author":"James","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111811062866300_B37","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T-cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.","volume":"99","author":"Yee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"95","key":"2019111811062866300_B38","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5","key":"2019111811062866300_B39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","article-title":"IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"issue":"4","key":"2019111811062866300_B40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/10430349950018634","article-title":"Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies.","volume":"10","author":"Alvarez-Vallina","year":"1999","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2019111811062866300_B41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.gt.3301051","article-title":"Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production.","volume":"7","author":"Weijtens","year":"2000","journal-title":"Gene Ther"},{"issue":"2","key":"2019111811062866300_B42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4049\/jimmunol.157.2.836","article-title":"Single chain Ig\/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.","volume":"157","author":"Weijtens","year":"1996","journal-title":"J Immunol"},{"issue":"5","key":"2019111811062866300_B43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1058","article-title":"T cell killing does not require the formation of a stable mature immunological synapse.","volume":"5","author":"Purbhoo","year":"2004","journal-title":"Nat Immunol"},{"issue":"1","key":"2019111811062866300_B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cellimm.2009.03.002","article-title":"IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells.","volume":"257","author":"Brown","year":"2009","journal-title":"Cell Immunol"},{"issue":"9","key":"2019111811062866300_B45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans.","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111811062866300_B46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/17\/3940\/1351355\/zh801712003940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/17\/3940\/1351355\/zh801712003940.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T05:22:16Z","timestamp":1686720136000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/17\/3940\/29880\/CD20specific-adoptive-immunotherapy-for-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,26]]},"references-count":46,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-387969","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.720026377.793531786","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,26]]}}}